• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » INC Research completes acquisition of Kendle International

INC Research completes acquisition of Kendle International

July 13, 2011
CenterWatch Staff

Raleigh, N.C.-based INC Research, a therapeutically focused CRO privately held by Avista Capital Partners and Ontario Teachers’ Pension Plan, has completed the acquisition of Kendle International in an all-cash transaction with a total equity value of approximately $232 million or $15.25 per share.

The combined company will operate as INC Research and be led by James T. Ogle, CEO. Serving in key corporate roles will be Jamie Macdonald, COO; John Potthoff, Ph.D., president; David Gill, CFO; Neil MacAllister, executive vice president, corporate and business development, INC Research and president, AVOS Consulting; and Mark Roseman, DSc, executive vice president, business development and marketing.

According to INC Research, with the addition of Kendle it now employs approximately 5,000 employees across six continents with experience in more than 100 countries, placing it among the top-tier CROs worldwide. With enhanced global scale, expanded therapeutic expertise and new levels of operational excellence, the new organization is more strongly positioned to deliver clinical trials of all sizes across the drug development spectrum, the company said. The transaction follows INC Research’s recent acquisition of Trident Clinical Research, now a wholly owned affiliate operating in Sydney, Brisbane, Melbourne, Adelaide, Auckland and Mumbai.

“Biopharmaceutical companies of all sizes are relying on outsourcing partners earlier in the clinical trials process,” said Ogle. “This transaction has enhanced our value proposition to global drug developers and given us a broader range of local operations with global oversight, allowing us to maintain high standards and quality results.”

INC Research has deployed a joint integration team that has begun fully integrating the two companies' customers, employees and services. This team will seek to ensure continued delivery on all current trials and maintain the company’s Trusted Process, advisory services and therapeutic expertise.

For the transaction J.P. Morgan Securities acted as Kendle’s financial advisor and Keating, Muething & Klekamp acted as its legal advisor. Morgan Stanley & Co. acted as financial advisor and Weil, Gotshal & Manges acted as legal advisor to INC Research.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing